CSF3 and acute myeloid leukemia: With low-dose cytarabine regimen, a significantly higher CR rate (65%) was achieved in hypo-AML than in RAEB/RAEB-t (0%) and overt AML in the elderly cases (27.3%).[6] Low-dose melphalan (oral 2 mg/d) has been reported as being highly effective in inducing complete remission in relatively high-risk patients such as, elderly patients with AML, AML with multilineage dysplasia and those with MDS.[14,15,16] The HAG regimen contains low-dose cytarabine and G-CSF, which may contribute to the higher CR rate observed in patients with hypo-AML.